Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results